吡莫地韋

吡莫地韋
臨床資料
商品名（英語：Drug nomenclature）	Pimodivir
法律規範狀態
法律規範	美：Investigational New Drug;
識別資訊
	IUPAC命名法 (2S,3S)-3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid; ;
CAS號	1629869-44-8
PubChem CID	67286591;
化學資訊
化學式	C20H19F2N5O2
摩爾質量	399.4
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES C1CC2CCC1[C@@H]([C@H]2NC3=NC(=NC=C3F)C4=CNC5=C4C=C(C=N5)F)C(=O)O;
	InChI InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1; Key:JGPXDNKSIXAZEQ-SBBZOCNPSA-N;

吡莫地韋（VX-787，JNJ-63623872）是一種抗病毒藥，被開發用於治療流感。它可作為流感病毒聚合酶鹼性蛋白2的抑制劑，並在II期臨床試驗中顯示出較好的療效。^[1]^[2]^[3]

參考文獻

^ Trevejo JM, Asmal M, Vingerhoets J, Polo R, Robertson S, Jiang Y, Kieffer TL, Leopold L. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study. Antivir Ther. 2018;23(4):335-344. PMID 29244026 doi:10.3851/IMP3212
^ Finberg RW, Lanno R, Anderson D, Fleischhackl R, van Duijnhoven W, Kauffman RS, Kosoglou T, Vingerhoets J, Leopold L. Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial. J Infect Dis. 2019 Mar 15;219(7):1026-1034. PMID 30428049 doi:10.1093/infdis/jiy547
^ Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019 Jul;167:45-67. PMID 30974127 doi:10.1016/j.antiviral.2019.04.006